HF
AKRO icon

HRT Financial’s Akero Therapeutics AKRO Stock Holding History

HRT Financial’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,581
Closed -$407K – 3114
2025
Q3 		$407K Buy
+8,581
New +$416K ﹤0.01% 1995
2024
Q4 		– Sell
-98,283
Closed -$2.82M – 2368
2024
Q3 		$2.82M Buy
+98,283
New +$2.56M 0.01% 734
2024
Q1 		– Sell
-36,639
Closed -$855K – 2233
2023
Q4 		$855K Buy
+36,639
New +$723K 0.01% 1070
2023
Q2 		– Sell
-16,489
Closed -$630K – 2394
2023
Q1 		$630K Buy
+16,489
New +$735K 0.01% 1216
2022
Q1 		– Sell
-12,881
Closed -$272K – 3029
2021
Q4 		$272K Buy
+12,881
New +$286K ﹤0.01% 2331

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HRT Financial's AKRO Position: Q4 2025 in Review

HRT Financial sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 8,581 shares — an estimated $407K sold.

HRT Financial first reported a position in AKRO in Q4 2021 and held it in 5 quarters. The position peaked at $2.82M in Q3 2024. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • HRT Financial reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • HRT Financial sold 8,581 Akero Therapeutics shares in Q4 2025, an estimated $407K.
  • HRT Financial first reported a position in Akero Therapeutics in Q4 2021 and held it in 5 quarters.
  • HRT Financial's Akero Therapeutics position peaked at $2.82M in Q3 2024.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.